Riding An Entrepreneurial Rocket To Financial success

How three Harvard grads formed an aerospace startup in a bedroom and six years later control a $45 million company FAIRFAX, VA.—David Thompson, Bruce Ferguson, and Scott Webster have boarded a rocket to success. The three young founders of Orbital’ Sciences Corp.—none older than 36—have created an aerospace firm that is playing David to the Goliaths of the rocket industry. After just six years they already have one viable product—a system for launching satellite

Written byJoseph Alper
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

FAIRFAX, VA.—David Thompson, Bruce Ferguson, and Scott Webster have boarded a rocket to success. The three young founders of Orbital’ Sciences Corp.—none older than 36—have created an aerospace firm that is playing David to the Goliaths of the rocket industry.

After just six years they already have one viable product—a system for launching satellites from the space shuttle—and several promising ones on the drawing board. Last year, INC. Magazine ranked OSO as one of the 20 fastest-growing high-technology companies in the nation, and the company was NASA’s 20th largest contractor. Ferguson, OSC’s vice president of finance, projects revenues to hit $45 million this year and says the company will be in the black for the third year in a row.

Only a decade ago, the thought of an aerospace scientist working for anyone but NASA or one of the aerospace giants such as Hughes Aerospace, McDonnell Douglas, or Lockheed was ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies